Tau oligomers: Cytotoxicity, propagation, and mitochondrial damage

Frontiers in Aging Neuroscience

Volumn 9, Issue APR, 2017, Pages

  Shafiei, Scott S ^a   Guerrero Muñoz, Marcos J ^b   Castillo Carranza, Diana L ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b HAMPTON UNIVERSITY   (United States)

Author keywords

Mitochondrial dysfunction; Propagation; Tau oligomers; Tau secretion; Tauopathy

Indexed keywords

DYNAMIN; MUSCARINIC RECEPTOR; OLIGOMER; PROTEOHEPARAN SULFATE; TAU PROTEIN;

ANNULAR PROTOFIBRIL; CELL ORGANELLE; CYTOTOXICITY; DEGENERATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ECTOSOME; ENDOCYTOSIS; EXOSOME; HUMAN; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PINOCYTOSIS; PROTEIN SECRETION; PROTEIN TRANSPORT; SHORT SURVEY;

EID: 85018381430     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2017.00083     Document Type: Short Survey

References (94)

1. Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K. L., Barde, Y. A., et al. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590. doi: 10.1046/j.1471-4159.2003.01879.x
2. Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., et al. (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584-1593. doi: 10.1038/nn.4132
3. Avila, J., Lucas, J. J., Perez, M., and Hernandez, F. (2004). Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384. doi: 10.1152/physrev.00024.2003
4. Ballatore, C., Lee, V. M., and Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672. doi: 10.1038/nrn2194
5. Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., et al. (2007). Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650-3662. doi: 10.1523/JNEUROSCI.0587-07.2007
6. Calafate, S., Buist, A., Miskiewicz, K., Vijayan, V., Daneels, G., de Strooper, B., et al. (2015). Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 11, 1176-1183. doi: 10.1016/j.celrep.2015.04.043
7. Castillo-Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., and Kayed, R. (2014b). Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J. Alzheimers Dis. 40(Suppl. 1), S97-S111. doi: 10.3233/JAD-132477
8. Castillo-Carranza, D. L., Lasagna-Reeves, C. A., and Kayed, R. (2013). Tau aggregates as immunotherapeutic targets. Front. Biosci. 5, 426-438. doi: 10.2741/S381
9. Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., et al. (2014a). Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260-4272. doi: 10.1523/JNEUROSCI.3192-13.2014
10. Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J. P., and Belting, M. (2013). Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. U.S.A. 110, 17380-17385. doi: 10.1073/pnas.1304266110
11. Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R. A., Frank, S., Hench, J., et al. (2013). Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U.S.A. 110, 9535-9540. doi: 10.1073/pnas.1301175110
12. Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., et al. (2009). Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913. doi: 10.1038/ncb1901
13. Cocucci, E., Racchetti, G., and Meldolesi, J. (2009). Shedding microvesicles: artefacts no more. Trends Cell Biol. 19, 43-51. doi: 10.1016/j.tcb.2008.11.003
14. Cowan, C. M., Bossing, T., Page, A., Shepherd, D., and Mudher, A. (2010). Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol. 120, 593-604. doi: 10.1007/s00401-010-0716-8
15. Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., et al. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7:42. doi: 10.1186/1750-1326-7-42
16. David, D. C., Hauptmann, S., Scherping, I., Schuessel, K., Keil, U., Rizzu, P., et al. (2005). Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 280, 23802-23814. doi: 10.1074/jbc.M500356200
17. Davizon, P., Munday, A. D., and López, J. A. (2010). Tissue factor, lipid rafts, and microparticles. Semin. Thromb. Hemost. 36, 857-864. doi: 10.1055/s-0030-1267039
18. de Calignon, A., Fox, L. M., Pitstick, R., Carlson, G. A., Bacskai, B. J., Spires-Jones, T. L., et al. (2010). Caspase activation precedes and leads to tangles. Nature 464, 1201-1204. doi: 10.1038/nature08890
19. Dennissen, F. J., Anglada-Huguet, M., Sydow, A., Mandelkow, E., and Mandelkow, E. M. (2016). Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau DeltaK280. Proc. Natl. Acad. Sci. U.S.A. 113, 11597-11602. doi: 10.1073/pnas.1603119113
20. Doeuvre, L., Plawinski, L., Toti, F., and Anglés-Cano, E. (2009). Cell-derived microparticles: a new challenge in neuroscience. J. Neurochem. 110, 457-468. doi: 10.1111/j.1471-4159.2009.06163.x
21. DuBoff, B., Götz, J., and Feany, M. B. (2012). Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75, 618-632. doi: 10.1016/j.neuron.2012.06.026
22. Dujardin, S., Bégard, S., Caillierez, R., Lachaud, C., Delattre, L., Carrier, S., et al. (2014a). Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS ONE 9:e100760. doi: 10.1371/journal.pone.0100760
23. Dujardin, S., Lécolle, K., Caillierez, R., Bégard, S., Zommer, N., Lachaud, C., et al. (2014b). Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol. Commun. 2:14. doi: 10.1186/2051-5960-2-14
24. Flach, K., Hilbrich, I., Schiffmann, A., Gärtner, U., Krüger, M., Leonhardt, M., et al. (2012). Tau oligomers impair artificial membrane integrity and cellular viability. J. Biol. Chem. 287, 43223-43233. doi: 10.1074/jbc.M112.396176
25. Gendreau, K. L., and Hall, G. F. (2013). Tangles, toxicity, and tau secretion in AD-new approaches to a vexing problem. Front. Neurol. 4:160. doi: 10.3389/fneur.2013.00160
26. Gerson, J. E., and Kayed, R. (2013). Formation and propagation of tau oligomeric seeds. Front. Neurol. 4:93. doi: 10.3389/fneur.2013.00093
27. Gerson, J. E., Castillo-Carranza, D. L., and Kayed, R. (2014b). Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. ACS Chem. Neurosci. 5, 752-769. doi: 10.1021/cn500143n
28. Gerson, J. E., Sengupta, U., Lasagna-Reeves, C. A., Guerrero-Muñoz, M. J., Troncoso, J., and Kayed, R. (2014a). Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2:73. doi: 10.1186/2051-5960-2-73
29. Gerson, J., Castillo-Carranza, D. L., Sengupta, U., Bodani, R., Prough, D. S., DeWitt, D. S., et al. (2016). Tau oligomers derived from traumatic brain injury cause cognitive impairment and accelerate onset of pathology in htau mice. J. Neurotrauma 33, 2034-2043. doi: 10.1089/neu.2015.4262
30. Goedert, M., Ghetti, B., and Spillantini, M. G. (2000). Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann. N. Y. Acad. Sci. 920, 74-83. doi: 10.1111/j.1749-6632.2000.tb06907.x
31. Gómez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., et al. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24. doi: 10.1002/ana.410410106
32. Gómez-Ramos, A., Díaz-Hernández, M., Rubio, A., Díaz-Hernández, J. I., Miras-Portugal, M. T., and Avila, J. (2009). Characteristics and consequences of muscarinic receptor activation by tau protein. Eur. Neuropsychopharmacol. 19, 708-717. doi: 10.1016/j.euroneuro.2009.04.006
33. Gómez-Ramos, A., Díaz-Hernández, M., Rubio, A., Miras-Portugal, M. T., and Avila, J. (2008). Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell. Neurosci. 37, 673-681. doi: 10.1016/j.mcn.2007.12.010
34. Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., and Trojanowski, J. Q. (2010). Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45, 30-40. doi: 10.1016/j.exger.2009.10.010
35. Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T., and Masliah, E. (1999). Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 28849-28852. doi: 10.1074/jbc.274.41.28849
36. Hawkins, B. E., Krishnamurthy, S., Castillo-Carranza, D. L., Sengupta, U., Prough, D. S., Jackson, G. R., et al. (2013). Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. J. Biol. Chem. 288, 17042-17050. doi: 10.1074/jbc.M113.472746
37. Holmes, B. B., and Diamond, M. I. (2014). Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J. Biol. Chem. 289, 19855-19861. doi: 10.1074/jbc.R114.549295
38. Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., et al. (2013). Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. U.S.A. 110, E3138-E3147. doi: 10.1073/pnas.1301440110
39. Hooper, N. M. (2011). Glypican-1 facilitates prion conversion in lipid rafts. J. Neurochem. 116, 721-725. doi: 10.1111/j.1471-4159.2010.06936.x
40. Hutton, M. (2000). Molecular genetics of chromosome 17 tauopathies. Ann. N. Y. Acad. Sci. 920, 63-73. doi: 10.1111/j.1749-6632.2000.tb06906.x
41. Iba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q., and Lee, V. M. (2013). Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33, 1024-1037. doi: 10.1523/JNEUROSCI.2642-12.2013
42. Ihara, Y. (2001). PHF and PHF-like fibrils-cause or consequence? Neurobiol. Aging 22, 123-126. doi: 10.1016/S0197-4580(00)00200-1
43. Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., et al. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397. doi: 10.1016/j.cell.2010.06.036
44. Khalyfa, A., and Gozal, D. (2014). Exosomal miRNAs as potential biomarkers of cardiovascular risk in children. J. Transl. Med. 12:162. doi: 10.1186/1479-5876-12-162
45. Kim, S. H., Vlkolinsky, R., Cairns, N., Fountoulakis, M., and Lubec, G. (2001). The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci. 68, 2741-2750. doi: 10.1016/S0024-3205(01)01074-8
46. Kozlov, M. M. (1999). Dynamin: possible mechanism of "Pinchase" action. Biophys. J. 77, 604-616. doi: 10.1016/S0006-3495(99)76917-1
47. Kuchibhotla, K. V., Wegmann, S., Kopeikina, K. J., Hawkes, J., Rudinskiy, N., Andermann, M. L., et al. (2014). Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. U.S.A. 111, 510-514. doi: 10.1073/pnas.1318807111
48. LaPointe, N. E., Morfini, G., Pigino, G., Gaisina, I. N., Kozikowski, A. P., Binder, L. I., et al. (2009). The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J. Neurosci. Res. 87, 440-451. doi: 10.1002/jnr.21850
49. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., and Kayed, R. (2011). Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 6:39. doi: 10.1186/1750-1326-6-39
50. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Kiritoshi, T., Neugebauer, V., et al. (2012a). Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2:700. doi: 10.1038/srep00700
51. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., et al. (2012b). Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959. doi: 10.1096/fj.11-199851
52. Lasagna-Reeves, C. A., Sengupta, U., Castillo-Carranza, D., Gerson, J. E., Guerrero-Muñoz, M., Troncoso, J. C., et al. (2014). The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol. Commun. 2:56. doi: 10.1186/2051-5960-2-56
53. Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159. doi: 10.1146/annurev.neuro.24.1.1121
54. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., et al. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479-489. doi: 10.1016/S0092-8674(00)80434-1
55. Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., et al. (2007). Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856-3861. doi: 10.1021/bi061359o
56. Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., and Takashima, A. (2006). Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci. Res. 54, 197-201. doi: 10.1016/j.neures.2005.11.009
57. Mathivanan, S., Ji, H., and Simpson, R. J. (2010). Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 73, 1907-1920. doi: 10.1016/j.jprot.2010.06.006
58. Medina, M., and Avila, J. (2014). The role of extracellular Tau in the spreading of neurofibrillary pathology. Front. Cell. Neurosci. 8:113. doi: 10.3389/fncel.2014.00113
59. Mirbaha, H., Holmes, B. B., Sanders, D. W., Bieschke, J., and Diamond, M. I. (2015). Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J. Biol. Chem. 290, 14893-14903. doi: 10.1074/jbc.M115.652693
60. Mondragón-Rodríguez, S., Trillaud-Doppia, E., Dudilot, A., Bourgeois, C., Lauzon, M., Leclerc, N., et al. (2012). Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 287, 32040-32053. doi: 10.1074/jbc.M112.401240
61. Morfini, G. A., Burns, M., Binder, L. I., Kanaan, N. M., LaPointe, N., Bosco, D. A., et al. (2009). Axonal transport defects in neurodegenerative diseases. J. Neurosci. 29, 12776-12786. doi: 10.1523/JNEUROSCI.3463-09.2009
62. Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381. doi: 10.1097/NEN.0b013e31825018f7
63. Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., et al. (2011). Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 286, 23063-23076. doi: 10.1074/jbc.M111.237974
64. Piccin, A., Murphy, W. G., and Smith, O. P. (2007). Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 21, 157-171. doi: 10.1016/j.blre.2006.09.001
65. Pooler, A. M., and Hanger, D. P. (2010). Functional implications of the association of tau with the plasma membrane. Biochem. Soc. Trans. 38, 1012-1015. doi: 10.1042/BST0381012
66. Pooler, A. M., Phillips, E. C., Lau, D. H., Noble, W., and Hanger, D. P. (2013a). Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389-394. doi: 10.1038/embor.2013.15
67. Pooler, A. M., Polydoro, M., Wegmann, S., Nicholls, S. B., Spires-Jones, T. L., and Hyman, B. T. (2013b). Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets. Alzheimers Res. Ther. 5:49. doi: 10.1186/alzrt214
68. Quintanilla, R. A., Matthews-Roberson, T. A., Dolan, P. J., and Johnson, G. V. (2009). Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J. Biol. Chem. 284, 18754-18766. doi: 10.1074/jbc.M808908200
69. Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., et al. (2006). Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U.S.A. 103, 11172-11177. doi: 10.1073/pnas.0603838103
70. Reed, L. A., Wszolek, Z. K., and Hutton, M. (2001). Phenotypic correlations in FTDP-17. Neurobiol. Aging 22, 89-107. doi: 10.1016/S0197-4580(00)00202-5
71. Rudinskiy, N., Hawkes, J. M., Wegmann, S., Kuchibhotla, K. V., Muzikansky, A., Betensky, R. A., et al. (2014). Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathol. Commun. 2:63. doi: 10.1186/2051-5960-2-63
72. Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., et al. (2012). Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287, 3842-3849. doi: 10.1074/jbc.M111.277061
73. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481. doi: 10.1126/science.1113694
74. Sengupta, U., Guerrero-Muñoz, M. J., Castillo-Carranza, D. L., Lasagna-Reeves, C. A., Gerson, J. E., Paulucci-Holthauzen, A. A., et al. (2015). Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol. Psychiatry 78, 672-683. doi: 10.1016/j.biopsych.2014.12.019
75. Simoneau, S., Rezaei, H., Salès, N., Kaiser-Schulz, G., Lefebvre-Roque, M., Vidal, C., et al. (2007). In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog. 3:e125. doi: 10.1371/journal.ppat.0030125
76. Spillantini, M. G., Van Swieten, J. C., and Goedert, M. (2000). Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Neurogenetics 2, 193-205. doi: 10.007/s100489900084
77. Spires, T. L., Orne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., et al. (2006). Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 168, 1598-1607. doi: 10.2353/ajpath.2006.050840
78. Tai, H. C., Serrano-Pozo, A., Hashimoto, T., Frosch, M. P., Spires-Jones, T. L., and Hyman, B. T. (2012). The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am. J. Pathol. 181, 1426-1435. doi: 10.1016/j.ajpath.2012.06.033
79. Takashima, A. (2013). Tauopathies and tau oligomers. J. Alzheimers Dis. 37, 565-568. doi: 10.3233/JAD-130653
80. Tanemura, K., Akagi, T., Murayama, M., Kikuchi, N., Murayama, O., Hashikawa, T., et al. (2001). Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol. Dis. 8, 1036-1045. doi: 10.1006/nbdi.2001.0439
81. Tanemura, K., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., Ichikawa, M., et al. (2002). Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci. 22, 133-141.
82. Tatebayashi, Y., Miyasaka, T., Chui, D. H., Akagi, T., Mishima, K., Iwasaki, K., et al. (2002). Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U.S.A. 99, 13896-13901. doi: 10.1073/pnas.202205599
83. Telling, G. C., Parchi, P., DeArmond, S. J., Cortelli, P., Montagna, P., Gabizon, R., et al. (1996). Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274, 2079-2082. doi: 10.1126/science.274.5295.2079
84. Théry, C., Ostrowski, M., and Segura, E. (2009). Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581-593. doi: 10.1038/nri2567
85. Tian, H., Davidowitz, E., Lopez, P., Emadi, S., Moe, J., and Sierks, M. (2013). Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int. J. Cell Biol. 2013:260787. doi: 10.1155/2013/260787
86. van Horssen, J., Otte-Höller, I., David, G., Maat-Schieman, M. L., van den Heuvel, L. P., Wesseling, P., et al. (2001). Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. 102, 604-614. doi: 10.1007/s004010100414
87. Ward, S. M., Himmelstein, D. S., Lancia, J. K., and Binder, L. I. (2012). Tau oligomers and tau toxicity in neurodegenerative disease. Biochem. Soc. Trans. 40, 667-671. doi: 10.1042/BST20120134
88. Winston, C. N., Goetzl, E. J., Akers, J. C., Carter, B. S., Rockenstein, E. M., Galasko, D., et al. (2016). Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement. 3, 63-72. doi: 10.1016/j.dadm.2016.04.001
89. Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., et al. (2001). Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714. doi: 10.1126/science.1062382
90. Witwer, K. W., Buzás, E. I., Bemis, L. T., Bora, A., Lässer, C., Lötvall, J., et al. (2013). Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2:20360. doi: 10.3402/jev.v2i0.20360
91. Wu, J. W., Herman, M., Liu, L., Simoes, S., Acker, C. M., Figueroa, H., et al. (2013). Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288, 1856-1870. doi: 10.1074/jbc.M112.394528
92. Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., et al. (2011). In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31, 13110-13117. doi: 10.1523/JNEUROSCI.2569-11.2011
93. Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., et al. (2014). Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387-393. doi: 10.1084/jem.20131685
94. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. doi: 10.1016/j.neuron.2007.01.010